Successful treatment of a patient with mitochondrial myopathy with alirocumab.
Alirocumab
Hypercholesterolemia
Mitochondrial myopathy
PCSK9 inhibitor
Journal
Journal of clinical lipidology
ISSN: 1933-2874
Titre abrégé: J Clin Lipidol
Pays: United States
ID NLM: 101300157
Informations de publication
Date de publication:
Historique:
received:
25
02
2020
revised:
26
05
2020
accepted:
19
07
2020
pubmed:
18
8
2020
medline:
18
9
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
A 48-year-old man presented to our lipid clinic with statin intolerance and elevated serum creatine kinase levels, being affected by mitochondrial myopathy because of heteroplasmic mitochondrial DNA missense mutation in MTCO1 gene (m.7671T>A). He had just been treated with a coronary artery bypass 4 years before because of acute coronary syndrome, and he had consistently high levels of both low-density lipoprotein cholesterol and triglycerides. Dyslipidemia was successfully treated using 75 mg of alirocumab subcutaneously every 2 weeks, 10 mg of ezetimibe daily, 2 g of marine omega-3 fatty acids daily, and 145 mg of micronized fenofibrate every 2 days. Although muscle weakness persisted, myalgia did not reoccur and serum creatine kinase levels remained almost stable over the time.
Identifiants
pubmed: 32800583
pii: S1933-2874(20)30217-8
doi: 10.1016/j.jacl.2020.07.007
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Electron Transport Complex IV
EC 1.9.3.1
cytochrome c oxidase subunit I, human
EC 1.9.3.1
alirocumab
PP0SHH6V16
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
646-648Informations de copyright
Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved.